733751-06-9Relevant academic research and scientific papers
Novel bicyclic compound as glucose-protein coupled receptor agonists
-
Paragraph 0071-0074; 0077; 0078; 0081, (2017/06/15)
The present invention relates to a novel bicyclic GPRC agonist and, more specifically, a novel bicyclic compound having an effect in promoting GPR119(Glucose-protein coupled receptor 119) activity, a composition containing the compound and a pharmaceutica
Synthesis and biological evaluation of pyrimidine derivatives with diverse azabicyclic ether/amine as novel GPR119 agonist
Yang, Zunhua,Fang, Yuanying,Park, Haeil
, p. 2515 - 2519 (2017/05/10)
A class of novel pyrimidine derivatives bearing diverse conformationally restricted azabicyclic ether/amine were designed, synthesized and evaluated for their GPR119 agonist activities against type 2 diabetes. Most compounds exhibited superior hEC50
Synthesis and biological evaluation of 5-nitropyrimidine analogs with azabicyclic substituents as GPR119 agonists
Yang, Zunhua,Fang, Yuanying,Pham, Tuan-Anh N.,Lee, Jongkook,Park, Haeil
, p. 1519 - 1521 (2013/03/14)
5-Nitropyrimidine analogs substituted with conformationally restricted azabicyclic amines and alcohols were prepared and evaluated their agonistic activity against human GPR119. The analogs bearing endo-azabicyclic amines and alcohols (7, 8, 11, and 12) e
Discovery of fused bicyclic agonists of the orphan G-protein coupled receptor GPR119 with in vivo activity in rodent models of glucose control
Semple, Graeme,Ren, Albert,Fioravanti, Beatriz,Pereira, Guillherme,Calderon, Imelda,Choi, Karoline,Xiong, Yifeng,Shin, Young-Jun,Gharbaoui, Tawfik,Sage, Carleton R.,Morgan, Michael,Xing, Charles,Chu, Zhi-Liang,Leonard, James N.,Grottick, Andrew J.,Al-Shamma, Hussein,Liang, Yin,Demarest, Keith T.,Jones, Robert M.
scheme or table, p. 3134 - 3141 (2011/06/26)
We herein outline the design of a new series of agonists of the pancreatic and GI-expressed orphan G-protein coupled receptor GPR119, a target that has been of significant recent interest in the field of metabolism, starting from our prototypical agonist
